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Abstract
The recent emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2), the underlying cause of Coronavirus Disease 2019 (COVID-19), has led to a worldwide
pandemic causing substantial morbidity, mortality, and economic devastation. In response,
many laboratories have redirected attention to SARS-CoV-2, meaning there is an urgent
need for tools that can be used in laboratories unaccustomed to working with coronaviruses.
Here we report a range of tools for SARS-CoV-2 research. First, we describe a facile single
plasmid SARS-CoV-2 reverse genetics system that is simple to genetically manipulate and
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can be used to rescue infectious virus through transient transfection (without in vitro tran-
scription or additional expression plasmids). The rescue system is accompanied by our
panel of SARS-CoV-2 antibodies (against nearly every viral protein), SARS-CoV-2 clinical
isolates, and SARS-CoV-2 permissive cell lines, which are all openly available to the scien-
tific community. Using these tools, we demonstrate here that the controversial ORF10 pro-
tein is expressed in infected cells. Furthermore, we show that the promising repurposed
antiviral activity of apilimod is dependent on TMPRSS2 expression. Altogether, our SARS-
CoV-2 toolkit, which can be directly accessed via our website at https://mrcppu-covid.bio/,
constitutes a resource with considerable potential to advance COVID-19 vaccine design,
drug testing, and discovery science.
Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of the
Coronavirus Disease 2019 (COVID-19) pandemic. SARS-CoV-2 emerged in late 2019 in the
western Chinese city of Wuhan, in Hubei Province, and following a rapid and explosive out-
break, spread to over 175 countries in the following months [1]. Despite an unprecedented
and globally coordinated response to stop the pandemic, over 92 million cases and 1.9 million
deaths (as of January 14, 2021) have so far been attributed to COVID-19 [2]. SARS-CoV-2 is a
member of the Betacoronavirus genus and is closely related to the SARS-CoV which caused an
outbreak of acute viral pneumopathy in 2002 to 2003 [3,4]. Data gathered throughout the 2020
COVID-19 pandemic indicate that SARS-CoV-2 is more transmissible than SARS-CoV [5],
reinforcing the need for effective therapeutic and preventative measures, including vaccines,
antivirals, and anti-inflammatory drugs to limit viral replication and/or acute lung inflamma-
tion. To date, a number of vaccine candidates, including an mRNA-based vaccine [6] and a
chimpanzee adenovirus-vectored vaccine (ChAdOx1-nCoV19) [7–9] have undergone Phase
III clinical trials and showed effective protection, including in patients over 65 years old. Like-
wise, monoclonal antibody treatments aimed at neutralising viral particles as a therapeutic
intervention for adult COVID-19 patients have recently been granted emergency FDA
approval [10–12].
The successful identification and characterisation of these and other SARS-CoV-2 vaccine
or drug candidates will require extensive characterisation of SARS-CoV-2 in vivo and in vitro,
and this in turn will rely upon validated laboratory resources to facilitate this research. Coro-
naviruses possess a particularly large RNA genome, where the replicase functions are carried
out by numerous nonstructural proteins (nsp), arising from cleavage of 2 large replicase poly-
proteins (termed ORF1a and ORF1b, respectively) [4]. Consequently, replication and tran-
scription of the genome is complex. Currently, a limited number of tools, including reverse
genetics (RG) strategies, have been described for this virus. The current RG systems are often
based on end-ligation cloning strategies and are reliant on in vitro transcription, with con-
structs expressing nucleocapsid protein provided in trans [13–15]. Moreover, the existing “full
length” yeast artificial chromosome (YAC) systems still require in vitro transcription coupled
with nucleocapsid expression in trans to rescue infectious virus [14]. Similarly, a recently
described bacterial artificial chromosome (BAC)-based infectious clone, though competent
both in vitro and in an in vivo hamster model of SARS-CoV-2 infection [16], is devoid of
reporter cassettes that, when inserted with fluorescent protein tags, markedly facilitate the
visualisation of infected cells and tissues. Here, we describe a variety of tools to facilitate
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SARS-CoV-2 research. First, we describe a user-friendly RG plasmid system, in which an
infectious cDNA (icDNA) clone of SARS-CoV-2, based on the Wuhan strain (Wuhan-Hu-1),
was generated using a low copy plasmid backbone (which facilitates rapid and straightforward
genetic manipulation). To increase the functionality of this system, we used conventional
methods to insert a variety of reporter cassettes (e.g., mCherry, ZsGreen, and Nanoluciferase
(NLuc)) into the functional icDNA genome. Because the viral genome is flanked by a eukary-
otic promoter and terminator, we show that infectious virus can be rescued by transient trans-
fection of a single plasmid species (with no DNA ligation or in vitro transcription required).
Using this system, we rescued infectious virus, at the first attempt, in 3 different countries
(which, crucially, had not worked with CoVs prior to 2020).
We further describe the production of a near-comprehensive panel of SARS-CoV-2 anti-
bodies (targeting all but 3 SARS-CoV-2 proteins) alongside a smaller panel of antibodies tar-
geting key SARS-CoV, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and
seasonal human coronavirus (HCoV) OC43 and 229E antigens. We demonstrate the utility of
these antibodies in a multitude of functional assays, such as western blotting (WB), immuno-
fluorescence (IF), and co-immunoprecipitation (co-IP) assays. Crucially, these antibodies can
reveal the abundance and location of most SARS-CoV-2 proteins at different stages of viral
replication, and through this approach, we provided what was, to the best of our knowledge (at
the time of first submission), the first evidence supporting protein expression of ORF10
(which has no ortholog in SARS-CoV). In addition, this resource also includes multiple clinical
isolates, as well as modified cell lines with increased susceptibility to SARS-CoV-2 infection,
which we have used to reveal the TMPRSS2-dependence of the potent anti-SARS-CoV-2 activ-
ity of apilimod.
As many labs worldwide pivot to identify drug and vaccine candidates to tackle COVID-19,
the resources and technologies described herein aim to accelerate COVID-19 research. Most
importantly, this coronavirus toolkit, including SARS-CoV-2 infectious clones, patient iso-
lates, cell lines, and antibodies, has been made openly available to research groups worldwide
through our user-friendly webpage (https://mrcppu-covid.bio/) and established
biorepositories.
Results
Design of SARS-CoV-2-Wuhan-Hu1 clone and rescuing of icDNA-derived
SARS-CoV-2
Because coronavirus genomes are substantially longer than those of most RNA viruses, many
coronavirus RG systems involve techniques not normally used in RNA virus rescue. Specifi-
cally, the in vitro transcription of multiple ligated cDNAs or the propagation of YACs are not
necessary for rescuing most RNA viruses. Thus, we sought to construct a simple and accessible
single-plasmid rescue system to accelerate COVID-19 research (particularly in laboratories
unaccustomed to working with coronaviruses).
We designed our SARS-CoV-2 infectious cDNA clone based on the Wuhan-Hu-1 isolate
and the viral cDNA was cloned into pCC1-4K, a derivative of the pCC1BAC (EPICENTRE).
Importantly, a substantial fraction of the regulatory sequences was removed to make the
pCC1-4K plasmid (which lacks an intact F factor). In the correct strains, the pCC1-4K system
is maintained at a single copy per cell. Because coronavirus-derived cDNA sequences can be
unstable when propagated in bacteria, the low copy number facilitates the simple genetic
manipulation of SARS-CoV-2 icDNA. Importantly, following successful genetic manipulation,
the presence of an arabinose-inducible origin in pCC1 means that supplementing bacterial
PLOS BIOLOGY A SARS-CoV-2 Coronavirus Toolkit for COVID-19 Research
PLOS Biology | https://doi.org/10.1371/journal.pbio.3001091 February 25, 2021 3 / 22
maltose-binding protein; MERS-CoV, Middle East
Respiratory Syndrome Coronavirus; MOI,
multiplicity of infection; NLuc, Nanoluciferase; nsp,
nonstructural proteins; RG, reverse genetics;
SARS-CoV-2, Severe Acute Respiratory Syndrome
Coronavirus 2; SV40, Simian Virus 40 terminator;
VA, Vero E6-ACE2; VAT, Vero E6-ACE2-TMPRSS2;
VT, Vero E6-TMPRSS2; WB, western blotting; wt,
wild-type; YAC, yeast artificial chromosome.
cultures with arabinose can greatly enhance DNA yield, and therefore large quantities of trans-
fection-quality DNA can be prepared using standard reagents.
We assembled the SARS-CoV-2 icDNA genome from 5 synthetic fragments, each flanked
by unique restriction sites SanDI (1524), PacI (8586), MluI (13956), Bsu36I (18176), and
BamHI (25313) (Fig 1A). A human cytomegalovirus (CMV) promoter was inserted at the
position corresponding to the 50 end of the genome, and a dual hepatitis delta virus (HDV)
ribozyme and Simian Virus 40 terminator (SV40) were added downstream of the poly-A tail at
the 30 end of the virus genome. These elements ensure efficient transcription and homogenous
30 end processing during the rescue of infectious virus. To enable direct visualisation and
quantification of replicating virus in cells, we also generated variants containing sequences
encoding for fluorescent (mCherry and ZsGreen) and bioluminescent (Nanoluciferase, or
NLuc) markers inserted into the plasmid backbone. To avoid deletion of viral sequences, the
markers were cloned in-frame after the C-terminus of the ORF7a protein using a foot-and-
mouth disease virus (FMDV) 2A “ribosomal skipping” linker (2A) to liberate the nascent
reporter protein from the ORF7a protein (Fig 1A).
Because plasmid clones harbouring the full-length SARS-CoV-2 genome could be unstable,
we transformed the wild-type (wt) rescue plasmid, picked 2 colonies, and passaged each line-
age through a series of 5 liquid cultures (summarised in Fig 1B). Bacterial cells were plated in
between each passage, and a single colony was used to initiate each subsequent liquid passage.
To validate plasmid integrity, a single colony derived from each lineage of the fifth liquid pas-
sage was chosen at random and “grown up” (1 litre culture induced with arabinose), and the
culture used to extract plasmid DNA. The plasmids were then sequenced with an average cov-
erage of 649 reads (wt 1) and 829 reads (wt 2) (S1 Fig). Using a conservative estimate of 1
duplication per hour of culture, the 2 sequenced colonies underwent over 100 divisions and
both colonies (out of over 1 × 1030 progeny) yielded DNA with the correct consensus
sequence. There were no subconsensus substitutions detected at a frequency greater than 5%
and in this approximately 35 kb construct, only 2 substitutions were detected in each lineage at
a frequency >1%. Thus, this plasmid system is stable for functional use. To rescue icDNA-
derived infectious viruses, we transfected BHK-21 cells with icDNA clones of SARS-CoV-2,
alongside derivatives harbouring mCherry, ZsGreen, and NLuc markers. The following day,
culture supernatant was used to inoculate subconfluent monolayers of Vero E6 cells. Following
4 days of culture, the virus-containing supernatant was harvested and the viral RNA was
extracted and sequenced (available at GenBank BioProject PRJNA658321). This confirmed
that “full-length” viruses had been rescued and that no nucleotide substitutions had accumu-
lated during the rescue and amplification steps. As expected, the frequency of subconsensus
substitutions was higher in the rescued viruses with 4 to 15 substitutions detected at a fre-
quency>5%. Crucially, the sequencing reads of the rescued viruses overwhelmingly mapped
to the viral genome (and not the flanking plasmid) indicating that we sequenced rescued viral
RNA and not contaminating plasmid DNA (Fig 1C and S1 Fig).
The resulting RG-rescued SARS-CoV-2 viruses replicated efficiently and could readily be
detected by IF microscopy using a commercial anti-SARS-CoV-2 nucleocapsid (N) antibody
(Fig 1D). Moreover, the rescued viruses induced cytopathic effect (CPE) and can be used in
conventional plaque assays (Fig 1E). When reporter expression and antigen expression were
compared, approximately 80% of infected Vero E6 cells expressed the reporter and N (Fig 1F
and 1G). The apparent 10% to 20% of infected cells that expressed N but not mCherry (Fig
1G) likely reflected asynchrony between N and mCherry expression as>95% of plaques from
the same passage were mCherry positive (Fig 1H). The NLuc and ZsGreen reporter systems
also facilitated the detection and quantification of recombinant SARS-CoV-2 replication in
infected cells. SARS-CoV-2-NLuc provided a robust readout of over 4 orders of magnitude of
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Fig 1. An openly available plasmid launched SARS-CoV-2 RG system. (A) Schematic of the design and construction of a pCC1-4K-SARS-CoV-
2-Wuhan-Hu-1 icDNA clone. Synthetic DNA fragments 1, 2, and 3 based on the SARS-CoV-2-Wuhan-Hu1 sequence were cloned into the pCC1
plasmids, and fragments 4 and 5 were cloned into high copy plasmid pUC57Kan by the gene synthesis company (Genscript). Fragments were
designed to contain specific restriction cloning sites SanDl, PacI, Mlul, Bsu36I, and BamHI for cloning purposes. Sequences encoding for mCherry,
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bioluminescence intensity (Fig 1I), and SARS-CoV-2-ZsGreen plaques were all ZsGreen posi-
tive at early passages (Fig 1J).
Reporter viruses are usually less replicatively fit than their unmodified counterparts, which
can lead to reporter-negative variants emerging during extended propagation. To assess the
stability of the ORF7a-2A-Reporter cassette, we passaged the SARS-CoV-2-mCherry virus 5
times in Vero E6 cells (Fig 1K). After 5 passages (P5), >95% of plaques were mCherry positive
in 2 out of 3 replicates (Fig 1L and 1M). In one of the replicates, however, an mCherry-nega-
tive population emerged by P4 and appeared to outcompete the parental mCherry virus (Fig
1L and 1M). To better characterise this process, we sequenced P2, P3, and P5 viral swarms
(Fig 1N and 1O). By P3, a deletion mutant was detected at low frequency (4%) that had lost
1,636 nucleotides (Δ1,636) encompassing the last 2 codons of ORF6 and all of ORF7a, all of
mCherry, all of ORF7b, and the majority of ORF8 (the last 2 codons remain). By P5, this variant
accounted for the majority of the viral swarm (approximately 60% to 90%). Thus, although the
majority of the replicates of the reporter viruses appear stable over many passages, deletion
variants can rapidly overrun the culture once they arise.
Generation of coronavirus antibodies
There is an urgent need to develop antibodies specifically targeting SARS-CoV-2 proteins to
accelerate COVID-19 research. We therefore generated a near-comprehensive panel of sheep
polyclonal antibodies against the structural, nonstructural, and accessory proteins of
SARS-CoV-2. In addition, we raised antibodies to the structural proteins of SARS-CoV and
MERS-CoV (S, E, M, and N proteins), as well as the N proteins of HCoV 229E and HCoV
OC43 (Fig 2A). To maximise the usefulness of these tools to the global scientific community,
we sought to experimentally validate these antibodies through established assays (although at
the time of submission, SARS-CoV-2 nsp4 and nsp6, and SARS-CoV and MERS-CoV S and
M antibodies were not yet available for validation).
The generation of the antibodies is illustrated in Fig 2B. Briefly, individual glutathione S-
transferase (GST)-tagged SARS-CoV-2 proteins were used to inoculate sheep, and immuno-
globulin G (IgG) was subsequently isolated and affinity purified using maltose-binding protein
ZsGreen, and NLuc markers were cloned in-frame to the C-terminus of the ORF7a protein via an FMDV 2A linker. (B) A summary of the passage
(P) history of the extensively propagated wt 1 and wt 2 plasmid preps (expanded 6 times on solid agar and 5 times in liquid culture prior to being
“grown up” in liquid culture for DNA extraction). (C) Summary plots of the number of reads mapping to the wt rescue plasmid and to the rescued
viral genome. (D) Detection of SARS-CoV-2 N antigen in Vero E6 cells infected with RG-rescued SARS-CoV-2-Wuhan-Hu-1. Cells were not
infected (Mock) or infected at MOI 1.0 for 48 h and then fixed and stained with mouse monoclonal anti-N antibody and counterstained with DAPI.
Cells were imaged using a confocal microscope. Scale bar = 50 μm. (E) Titre of the mCherry virus (plaque forming units on Vero E6 cells) following
propagation in Vero E6 cells (P3). (F) Detection of infected Vero E6 cells using the RG-rescued SARS-CoV-2-mCherry. Cells were infected for 48 h
at MOI 1.0, then fixed, stained with anti-N antibody, and imaged as in (D). Scale bar = 50 μm. (G) Quantification of mCherry and N expression in
Vero E6 cells infected with SARS-CoV-2-mCherry at an MOI of 0.1 for 48 h. Fixed and permeabilised cells were stained for N protein and with
Hoechst 33342 (2 μg/ml). Cells were imaged using the Celigo Imaging Cytometer to identify the proportion of infected cells positive for mCherry
and/or N protein. (H) Fixed plaque assays were scanned using a Celigo Imaging Cytometer (Nexcelom Bioscience) using the red channel to visualise
mCherry. The cells were then subsequently stained with Coomassie staining solution and imaged again. (I) Detection of viral replication in infected
Vero E6 cells using the RG-rescued SARS-CoV-2-NLuc. Cells were not infected (Mock) or infected at MOI 1.0 for 24 h, then lysed. NLuc activity
was measured in the lysate using a luminometer. (J) Fluorescent plaques of the SARS-CoV-2-ZsGreen virus were visualised using the green channel
as in panel H. (K) A schematic of the passage (P) history of the SARS-CoV-2 mCherry virus used to assess reporter stability. Each filled circle
represents 1 day of propagation. (L) Plaque assays of passages 3 to 5 were scanned (Celigo) as in (H). The percentage of plaques visible following
Coomassie staining that were mCherry-positive in the linear range of the dilution series (total plaque number in the range of 22 to 55 for each
replicate) are plotted for each lineage at each passage. (M) Typical images of fluorescent plaques used for the quantification in (L) are shown. (N) A
summary of the variation generated during the passage of the mCherry virus summarised in panel K. The variation is detailed in S1 Table. (O) The
percentage of the viral swarm displaying all variants that exceed 25% of the swarm at any time point is shown. The low-level deletion of the furin
cleavage site is also highlighted for interest. The data underlying Fig 1E, 1G, 1I and 1L may be found in S1 Data. FMDV, foot-and-mouth disease
virus; icDNA, infectious cDNA; MOI, multiplicity of infection; NLuc, Nanoluciferase; RG, reverse genetics; SARS-CoV-2, Severe Acute Respiratory
Syndrome Coronavirus 2; wt, wild-type.
https://doi.org/10.1371/journal.pbio.3001091.g001
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Fig 2. Production and validation of a near-comprehensive panel of openly available SARS-CoV-2 and coronavirus
antibodies. (A) Schematic representation of the SARS-CoV-2 and other coronavirus-processed proteins for which
antibody synthesis and validation is described in this study. All antibodies (and corresponding proteins and cDNAs)
listed are available upon request at https://mrcppu-covid.bio/. Accession numbers for the sequences utilised can be
found in S2 Table and at https://mrcppu-covid.bio/. (B) A schematic illustrating the method of production for the
antibodies shown in (A), utilising N (nucleocapsid) as an example. Each cDNA encoding a coronavirus protein was
cloned into both pGex (carrying a GST tag) and pMex (MBP tag) plasmids, in order to yield corresponding GST- and
MBP-tagged viral proteins. Sheep were subsequently immunised by utilising the GST-tagged proteins as antigens. At
day 7 postimmunisation, serum was harvested and antibodies were affinity purified using the corresponding MBP-
tagged protein. Additional inoculations (up to 5 in total) occurred 28 days apart. Exceptions to this method occurred
for SARS-CoV-2 ORF7a, S, and S-RBD antibodies, where the MBP-tagged proteins were used as antigens, and after
harvest, serum was again purified against the MBP-tagged protein, followed by depletion of the antibody against MBP.
The SARS-CoV-2 S antibody was purified using protein G Sepharose chromatography. (C) IF validation for three of
the antibodies (against nonstructural nsp2, structural N, and accessory ORF3a proteins) shown in (A) was conducted
in Vero E6 cells that were uninfected (mock) or infected with the SARS-CoV-2 England-02 virus at an MOI of 0.1 for
48 h prior to fixation, permeabilization, and staining. IF validation for the remaining antibodies in (A) is shown in S2
Fig. (D) WB validation for the 3 antibodies shown in (C) was conducted using Vero E6 cells that were uninfected
(mock) or infected with England-02 virus at an MOI of 0.1 or 1 (as indicated) for 72 h followed by WB analysis of
whole cell lysates. WB validation for the remaining antibodies in (A) is shown in S3 and S4 Figs. (E) IP validation for
the 3 antibodies shown in (C) was conducted using Vero E6 cells that were uninfected (mock) or infected with
England-02 virus at an MOI of 0.1 for 3 days. IP validation for the remaining antibodies in (A) is shown in S4 and S5
Figs. (F) Immunostaining of cells either uninfected (mock) or infected with the RG-rescued SARS-CoV-2 and its
mCherry and NLuc derivatives. Cells were stained using the N antibody utilised in (C–E) and imaged using a Celigo
imaging cytometer. (G) WB validation of Vero E6 cells infected for 48 h with the RG viruses shown from Fig 1A for 48
h, using the 3 antibodies shown in (C–E). GST, glutathione S-transferase; IB, immunoblotting; IF,
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(MBP)-tagged variants of each viral protein. To validate our panel of antibodies, we initially
examined their utility in indirect IF confocal microscopy. Vero E6 cells were mock infected or
infected with SARS-CoV-2 England-02 (from Public Health England) at multiplicity of infec-
tion (MOI) 0.1 for 48 h, and then fixed and stained with each antibody. Antigen staining was
highly specific to SARS-CoV-2-infected cells, exemplified by the staining of ORF3a, nsp2, and
N proteins (Fig 2C). Antibodies raised against the other SARS-CoV-2 proteins were also
highly specific, and more importantly, revealed the distinct staining and spatial distribution
profiles of most SARS-CoV-2 proteins (S2 Fig).
In a similar fashion, we validated our panel of antibodies targeting SARS-CoV-2 proteins
using WB. Vero E6 cells were infected with the England-02 isolate of SARS-CoV-2 at MOI 0.1
or 1 (as indicated) for 72 h (to ensure that most of the culture was infected using both multi-
plicities). Importantly, we were able to detect all available SARS-CoV-2 proteins using our
antibodies, again exemplified by ORF3a, N, and nsp2 (Fig 2D) with the data for all remaining
antibodies shown in S3 Fig. Interestingly, previous work has proposed that the ORF10 protein
is unlikely to be expressed and may be a misannotation [17]. Remarkably, ORF10 was specifi-
cally detected in infected cells by WB and IF using our antibodies (S2 and S3 Figs).
Furthermore, in the small number of instances examined, substantial cross-reactivity of the
antibodies was observed. For example, the antibodies raised against SARS-CoV N, MERS-CoV
N, and HCoV OC43 N efficiently recognised SARS-CoV-2 N, whereas cross-reactivity was not
observed for antibodies raised against N from the alphacoronavirus HCoV 229E (S4 Fig).
In addition to IF and WB, we examined the utility of our panel of antibodies in immuno-
precipitation (IP) assays. Here, Vero E6 cells were infected with England-02 for 3 days at MOI
0.1. Interestingly, the antibodies generally appeared more sensitive in IP assays than WB, and
anti-HCoV 229E N cross-reactivity with SARS-CoV-2 N that was not observed by WB was evi-
dent by IP (S4 Fig). Although cross-reactivity was present for SARS-CoV E, no cross-reactivity
was observed by IP or WB using anti-MERS-CoV E and SARS-CoV-2 antigens (S4 Fig).
Importantly, the antibodies resulted in efficient and specific IP of all but one (envelope [E]) of
the SARS-CoV-2 proteins we raised antibodies to (Fig 2E and S5 Fig).
Next, we validated our SARS-CoV-2 N antibody in cells infected with the icDNA-derived
viruses. Vero E6 cells were infected with the RG-rescued SARS-CoV-2-Wuhan-Hu-1 (wt),
SARS-CoV-2-NLuc, or SARS-CoV-2-mCherry for 48 h, and N protein was detected by IF (Fig
2F). Similarly, ORF3a, nsp2, and N proteins were detected in Vero E6 cell lysates after infec-
tion with all the RG viruses from Fig 1A, confirming the utility of our antibody panel (Fig 2G).
As nearly all antibodies are compatible with IF, WB, and IP, they represent an invaluable
resource to researchers investigating SARS-CoV-2 and COVID-19.
We next investigated whether our antibody panels could be a useful tool in the study of pro-
tein–protein interactions, for which co-IP is a common technique. We performed co-IPs to
look at interactions between different viral proteins based on studies performed with other
CoVs [18–21]. Using lysates from infected Vero E6 cells (England-02, MOI 0.1), we first
immunoprecipitated ORF3a protein using our ORF3a antibody and probed for the presence
of spike (S) protein and ORF3a (Fig 3A) [18–21]. This revealed a predicted interaction
between SARS-CoV-2 S and the accessory protein ORF3a, that had been observed in
SARS-CoV. Likewise, we performed co-IPs and confirmed interactions between the
SARS-CoV-2 nsp12 and nsp13 proteins (Fig 3B) [22]. In addition, we revealed a predicted
immunofluorescence; IP, immunoprecipitation; MBP, maltose-binding protein; MERS-CoV, Middle East Respiratory
Syndrome Coronavirus; MOI, multiplicity of infection; NLuc, Nanoluciferase; RG, reverse genetics; SARS-CoV-2,
Severe Acute Respiratory Syndrome Coronavirus 2; WB, western blotting; wt, wild-type.
https://doi.org/10.1371/journal.pbio.3001091.g002
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interaction between SARS-CoV-2 N and M proteins (Fig 3C). Altogether, our coronavirus
toolkit’s near-comprehensive SARS-CoV-2 antibody panel will greatly facilitate the study of
coronavirus protein–protein interactions.
Generation of SARS-CoV-2 permissive cell lines
SARS-CoV-2 has been shown to infect a variety of cell types, in particular nasal, epithelial, and
lung (bronchoalveolar, bronchial, and epithelial) cells [13]. In addition, multiple reports indi-
cate that gut epithelial and brain cells may also be natural targets of infection [23,24]. In
humans, angiotensin-converting enzyme 2 (ACE2) is the main receptor and the TMPRSS ser-
ine proteases cleave the viral S protein, priming it for infection. Importantly, blockade/inhibi-
tion of these proteins has been shown to inhibit viral infection [25]. Because many cell lines
derived from human lung are not susceptible to SARS-CoV-2 infection, such as A549 cells, we
sought to engineer susceptibility in cell lines that can easily be adapted for many assays
(including medium- to high-throughput formats). We transduced Vero E6 and A549 epithelial
cell lines using LV lentiviral vectors to generate ACE2 and TMPRSS2-expressing cell lines, as
well as double-expressing, ACE2-TMPRSS2 lines (Fig 4A). We visualised ACE2 and
TMPRSS2 expression by WB (Fig 4B) and also assessed ACE2 expression using IF (Fig 4C–
4F). The modified cell lines expressed ACE2 at higher levels than Calu-3 and Vero E6 cells
(Fig 4B) and exogenous TMPRSS2 expression reduced ACE2 expression as has been reported
previously [26]. Notably, in both cell backgrounds, exogenous ACE2 increased the susceptibil-
ity to infection, increasing the clarity of plaques in Vero E6 cells and converting A549s from
nonsusceptible to permissive target cells (Fig 4G–4I). The exogenous expression of TMPRSS2
alone, in Vero E6 cells, increased the size of the plaques. Interestingly, Vero E6-ACE2-
TMPRSS2 (VAT cells) yielded larger and clearer plaques (Fig 4G), which were more suscepti-
ble to infection as evidenced by the>10-fold increase in pfu/ml relative to unmodified cells
Fig 3. Usage of our toolkit antibodies to demonstrate or confirm SARS-CoV-2 protein interactions. (A) A co-IP
was performed using lysates from Vero E6 cells infected with England-02 at MOI 0.1 for 3 days. Using the specific anti-
ORF3a antibody described herein, SARS-CoV-2 ORF3a was immunoprecipitated (alongside a preimmune IgG
control), and the immune complexes were western blotted for the presence of SARS-CoV-2 spike (S) and ORF3a. (B)
As in (A), SARS-CoV-2 nsp13 (or IgG control) was immunoprecipitated and the immune complexes were probed for
nsp13 and nsp11/12 by WB. (C) As in (A, B), SARS-CoV-2 N (or IgG control) was immunoprecipitated and the
immune complexes were probed for matrix (M) and N by WB. co-IP, co-immunoprecipitation; IB, immunoblotting;
IgG, immunoglobulin G; MOI, multiplicity of infection; SARS-CoV-2, Severe Acute Respiratory Syndrome
Coronavirus 2; WB, western blotting.
https://doi.org/10.1371/journal.pbio.3001091.g003
PLOS BIOLOGY A SARS-CoV-2 Coronavirus Toolkit for COVID-19 Research
PLOS Biology | https://doi.org/10.1371/journal.pbio.3001091 February 25, 2021 9 / 22
PLOS BIOLOGY A SARS-CoV-2 Coronavirus Toolkit for COVID-19 Research
PLOS Biology | https://doi.org/10.1371/journal.pbio.3001091 February 25, 2021 10 / 22
(Fig 4H). Similar results were observed in AAT (A549-ACE2-TMPRSS2) cells, where exoge-
nous TMPRSS2 expression greatly increased plaque size and clarity, and modestly increased
the number of plaques (Fig 4I).
Crucially, these modified cell lines are suitable for cytopathic effect (CPE)-based assays.
CPE assays can be useful tools in compound screening and compound characterisation, and
these cell lines provide a clear output for medium-throughput screening. For illustration,
using VA (Vero E6-ACE2) cells, we examined potential inhibitory compounds using condi-
tions where a fixed dose of SARS-CoV-2 would cause substantial CPE, resulting in the cell
monolayer being “cleared” in the absence of any inhibitory compound. Virus-induced CPE
was effectively abrogated following treatment with apilimod, a phosphatidylinositol-3-phos-
phate 5-kinase (PIKfyve) inhibitor (Fig 4J). In contrast, ribonucleoside analogues remdesivir
and EIDD-2801 were less effective, but showed dose-dependent inhibition, while nafamostat,
a serine protease inhibitor, displayed no inhibitory effect against SARS-CoV-2. Importantly,
the inhibitory effect of apilimod was lost in the presence of TMPRSS2 (VAT cells), whereas the
inhibitory effects displayed by remdesivir and EIDD-2801 were unaffected (Fig 4J), suggesting
that apilimod’s mode of action may be ineffective when TMPRSS2-dependent infection
occurs. These observations were recapitulated in AA (A549-ACE2) and AAT cells (Fig 4K).
The CPE-based assays are also quantitative, allowing dose response curves to be generated and
EC50 values to be calculated. For example, dose response curves of apilimod inhibition of
SARS-CoV-2 in AA and AAT cells are shown in Fig 4L. Moreover, the CPE assays can be mul-
tiplexed with other assays to monitor compound toxicity in parallel (Fig 4M and 4N), and the
utility of the AA and AAT cells is indicated in S6 Fig, where these cells were used to consider
the ability of a panel of compounds to inhibit SARS-CoV-2.
Establishment and analysis of clinical isolates
The modified cell lines forming part of this resource are also useful for isolating and character-
ising SARS-CoV-2 from clinical samples [27]. We have isolated 3 SARS-CoV-2 viruses,
CVR-GLA-1, CVR-GLA-2, and CVR-GLA-3, from samples collected from patients hospital-
ised in Scotland (2 from sputum samples, one from a bronchoalveolar lavage (BAL) sample).
Using our modified cell lines to characterise the plaque phenotypes of these isolates, we found
that the CVR-GLA virus isolates all caused larger plaques than England-02 (Fig 5A and 5C),
consistent with the enhanced particle infectivity proposed for the D614G substitution [28]. In
addition, while titres across isolates were generally similar to those of England-02, they were
Fig 4. Conventional cell lines modified to express ACE2 and TMPRSS2 lentiviruses have utility in SARS-CoV-2 phenotypic assays. (A) A schematic illustrating
the LV-ACE2 and LV-TMPRSS2 lentiviruses that have been used to transduce multiple cell lines. The corresponding abbreviations of the modified lines are also
shown. (B) The abundance of ACE2 and TMPRSS2 in Vero E6 cells, A549 cells and derivatives modified to express exogenous ACE2 and/or TMPRSS2 was assessed
by WB. Permissive Calu-3 and Caco-2 samples were included for reference. Two actin blots are presented as different samples of equivalent cells were used to stain for
ACE2 and TMPRSS2. (C) ACE2 intensity values from confocal microscopy images of ACE2 and Hoechst-stained Vero E6 cells and VA, VT, and VAT derivatives
were measured using Cell Profiler (cellprofiler.org). (D) Randomly selected confocal microscopy images used for the quantification in (C) are shown. (E) As in panel
C, using stained A549 cells, as well as AA and AAT cell derivatives. (F) Randomly selected confocal microscopy images used for the quantification in (E) are shown.
(G) The plaque phenotype produced by the same preparation of SARS-CoV-2 England-02 on Vero E6 cells and VA, VT, and VAT derivatives. (H) As in (G),
indicating the titre (in pfu/ml) of the same preparation of SARS-CoV-2 England-02 in cells with or without exogenous ACE2 and/or TMPRSS2. (I) As in panel G, AA
and AAT derivatives of A549 cells were infected with SARS-CoV-2 England-02 to observe the plaque phenotype. (J) An example of a phenotypic well clearance/
monolayer integrity assay used to assess the anti-SARS-CoV-2 activity of various compounds (nafamostat, apilimod, EIDD_2801, or remdesivir). The cells were
treated with 2-fold serially diluted compound (10 μM to 20 nM) before being mock infected or infected with SARS-CoV-2. At 72 h postinfection, the monolayers were
fixed and Coomassie-stained before scanning using a Celigo imaging cytometer. (K) As in panel J, well clearance assays in AA and AAT cells using SARS-CoV-2
England-02 are shown. (L) Quantification of the anti-SARS-CoV-2 activity of apilimod in AA and AAT cells. The mean and standard error of 4 replicates are plotted.
(M) Dose response curve of remdesivir using the well-clearance assay in AA cells (as in panel K) multiplexed with a dead cell protease toxicity assay. The mean and
standard error of 4 replicates are plotted. (N) as in panel M using AAT cells. The data underlying Fig 4C, 4E, 4H, 4L, 4M and 4N may be found in S1 Data. AA,
A549-ACE2; AAT, A549-ACE2-TMPRSS2; ACE2, angiotensin-converting enzyme 2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; VA, Vero
E6-ACE2; VAT, Vero E6-ACE2-TMPRSS2; VT, Vero E6-TMPRSS2; WB, western blotting.
https://doi.org/10.1371/journal.pbio.3001091.g004
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Fig 5. Toolkit of SARS-CoV-2 clinical isolates. (A) A comparison of plaque phenotypes in VAT cells from the 3
SARS-CoV-2 viruses isolated in this study and the England-02 SARS-CoV-2 virus. (B) A comparison of viral titers (in
pfu/ml) of the 3 SARS-CoV-2 viruses isolated in this study and the England-02 SARS-CoV-2 virus in AA, AAT, Vero
E6 (E6), VA, and VAT cells. All cells with exogenous ACE2 or TMPRSS2 were transduced with the lentiviruses
described in Fig 4. (C) Quantification of plaque area (in mm2) was calculated in ImageJ (plaques not overlapping other
plaques or the side of the well) from 4 replicates of the data presented in (A) and (B). Significance was determined
using a Mann–Whitney U test. (D) A table showing the amino acid substitutions present in England-02 and 3
SARS-CoV-2 viruses isolated from clinical samples in this study, relative to Wuhan-Hu-1 (NC_045512). CVR-GLA-1
(MT882022) was isolated from sputum (CVR837 [EPI_ISL_461705]), CVR-GLA-2 (MT906650) was isolated from
sputum (CVR2224 [EPI_ISL_448167], and CVR-GLA-3 (MT906649) was isolated from bronchoalveolar lavage
(CVR3899_BAL [EPI_ISL_490695]). (E) IF of the 3 SARS-CoV-2 viruses isolated in this study and the England-02
SARS-CoV-2 virus in AAT cells (at MOI 0.01 for 48 h), using ORF3a, N, and nsp2 antibodies, as in Fig 2. The data
underlying Fig 5B and 5C may be found in S1 Data. AA, A549-ACE2; AAT, A549-ACE2-TMPRSS2; ACE2,
angiotensin-converting enzyme 2; IF, immunofluorescence; MOI, multiplicity of infection; SARS-CoV-2, Severe Acute
Respiratory Syndrome Coronavirus 2; VA, Vero E6-ACE2; VAT, Vero E6-ACE2-TMPRSS2.
https://doi.org/10.1371/journal.pbio.3001091.g005
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increased in the presence of exogenous ACE2 and further increased by the presence of exoge-
nous ACE2 and TMPRSS2, in line with our earlier observations (Fig 5B).
Clinical isolates can be particularly useful given the interest in phenotypic variation as the
pandemic unfolds, and for this reason, these viruses were sequenced to identify amino acid
substitutions relative to Wuhan-1 and England-02 (Fig 5D). For example, variants such as
D614G in spike (S), which occurs in all of our isolates, have been the subject of intense investi-
gation [28]. Moreover, CVR-GLA-2 exhibits the N439K substitution in S that has also been
linked to immune escape from neutralising antibodies [29].
We used our antibody panel to validate the 3 CVR-GLA isolates by IF. AAT cells were unin-
fected or infected at MOI 0.01 for 48 h with England-02, CVR-GLA-1, CVR-GLA-2, or
CVR-GLA-3. The cells were then probed with antibodies against ORF3a, nsp2, and N. As
observed in Fig 2C, each of these antibodies displayed strong specificity against their target
proteins expressed by all 3 viruses (Fig 5E), further validating the reagents generated in this
study.
Because most viruses become tissue culture-adapted when they are extensively passaged in
vitro, we sought to evaluate whether the human AAT cells might be an alternative substrate to
African green monkey Vero E6 cells for amplifying SARS-CoV-2. We passaged the
CVR-GLA-1 isolate on Vero E6 cells and AAT cells (Fig 6A) and sequenced the P2 and P6
swarms (Fig 6B). Strikingly, there was little overlap between the variants observed during pas-
sage of the mCherry (Fig 1N and 1O and S1 Table) and GLA-1 (Fig 6B and S1 Table) viruses
in Vero E6 cells, making it difficult to draw generalisable conclusions. We specifically exam-
ined the furin cleavage site in our sequencing data as variation in this region has received a lot
of attention. The multibasic S1/S2 furin cleavage site in SARS-CoV-2 S is essential for the
infection of human lung cells [30], and multiple studies have reported that this site can be rap-
idly lost during passage in Vero E6 cells [31,32], likely driven by the enhanced growth of furin
deletion mutants in Vero E6 cells [33]. In the 6 lineages of SARS-CoV-2-mCherry and
CVR-GLA-1 that were propagated in Vero E6 cells, only 1 lineage out of 6 exhibited a deletion
of the furin site at>0.5% abundance. Notably, in lineages that did contain a furin cleavage site
deletion (2/6), the deletion variant did not overrun the culture (and even decreased slightly in
frequency in 1 lineage), suggesting that these mutants did not have a substantial growth advan-
tage in Vero E6 cells. Surprisingly, while CVR-GLA-1 passaged in AAT cells only lost the furin
Fig 6. Sequence changes observed in SARS-CoV-2 CVR-GLA-1 following in vitro propagation. (A) A schematic of
the passage history of the SARS-CoV-2 CVR-GLA-1 virus in Vero E6 and AAT cells. Each filled circle represents 1 day
of propagation. (B) A summary of the variation generated during the passage of the CVR-GLA-1 virus indicated in
panel A. The variation is detailed in S1 Table. The percentage of the viral swarm displaying all variants that exceed 5%
or 25% of the swarm at any time point is shown. The percentage occurrence of several deletion mutants is highlighted
for interest. AAT, A549-ACE2-TMPRSS2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.
https://doi.org/10.1371/journal.pbio.3001091.g006
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cleavage site in 1 of 3 replicates (at 1.46%), 1 replicate did contain a deletion mutant near this
site at a frequency of approximately 10%. Thus, the AAT cells appear worse than the Vero E6
cells at preserving the integrity of the SARS-CoV-2 furin cleavage site during passage.
These data highlight the heterogeneous nature of SARS-CoV-2 propagation, where virus
strain, cell culture conditions, and passaging protocol all likely influence lab-to-lab variation of
virus stocks. Moreover, these data underscore the importance of facile, robust, high fidelity
rescue systems (such as the plasmid system described herein) for generating uniform
SARS-CoV-2 virus stocks that avoid the variation introduced when viral stocks are extensively
passaged.
Discussion
The COVID-19 pandemic has spurred unprecedented global efforts aimed at identifying vac-
cine candidates, antiviral compounds, or anti-inflammatory strategies to prevent SARS-CoV-2
infection or limit pathology. One of the most important factors driving this fast-paced field is
the large-scale scientific collaboration and sharing of data emanating from outbreak sites since
the start of the pandemic [14,15,34,35]. Further experimental work requires access to clinical
isolates and systems that allow genetic manipulation of SARS-CoV-2. In this report, we
describe the development of a research toolkit for studying SARS-CoV-2. First, we showed the
generation of a plasmid-launched RG system for SARS-CoV-2 assembled using publicly avail-
able sequences of the original SARS-CoV-2 Wuhan-Hu-1 virus isolate. By using an inducible
single-copy plasmid backbone, the cDNA of the full-length genome can be stably amplified.
Moreover, this single plasmid approach dispenses of the need for approximately 30 kb of
error-prone in vitro transcription and assembly of multiple DNA fragments, and it does not
require N expression in trans. The result is a highly versatile system that simply requires trans-
fection of DNA into cells, after which replication-competent SARS-CoV-2 can be harvested
from cell culture supernatants. Notably, during this study, infectious virus was rescued at the
first attempt in multiple laboratories (in 3 different countries) that had not previously rescued
infectious CoVs. Furthermore, this SARS-CoV-2 construct is readily amenable to genetic
manipulation (to study variants) and insertion of reporters, such as fluorescent or biolumines-
cent proteins, that can be used in a variety of in vitro and in vivo assays and enable direct
detection and quantification of in-cell viral replication kinetics. Importantly, the ease of
manipulation of the constructs described herein is best exemplified by the fact that the reporter
viruses described herein were constructed in multiple laboratories that had no prior experi-
ence of generating CoV reporter systems.
As a further part of our SARS-CoV-2 coronavirus toolkit, we describe a near-comprehen-
sive panel of antibodies targeted against nearly all SARS-CoV-2 proteins and key structural
proteins of SARS-CoV and MERS-CoV. These antibodies demonstrated high specificity, are
compatible with the “go-to” virological techniques optimised for the detection and quantifica-
tion of viral infection (e.g., IF and WB), and are also very useful in probing viral protein–pro-
tein interactions. Indeed, these antibodies have already been used in high-profile COVID-19
publications [36,37]. As an additional example of the utility of these antibodies, we confirmed
SARS-CoV-2 ORF10 protein expression (by IF, WB, and IP) in infected cells. Because ORF10
has no ortholog in SARS-CoV and ORF10 protein was previously predicted not to be
expressed in infected cells [17], detection of ORF10 protein expression confirms that this ORF
is a point of notable genomic divergence from SARS-CoV and could therefore be a determi-
nant of the divergent transmissibility/pathology caused by SARS-CoV-2.
Antiviral drug screening and validation of FDA-approved drugs for repurposing to treat
SARS-CoV-2 infection are key approaches in the search for effective antivirals. While modified
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cell lines are relatively easy to generate, they have been included in this toolkit as they are still
useful tools for dissecting SARS-CoV-2 biology. For example, apilimod is a PIKfyve inhibitor
and PIKfyve blockade potently inhibits SARS-CoV-2 infection in some cells [38,39], likely
through interfering with endosomal trafficking [40]. Such an approach has been suggested to
be unaffected by TMPRSS2 expression because PIKfyve inhibition could be independent and
downstream of the proteases that prime the SARS-CoV-2 glycoprotein for fusion [41]. How-
ever, in contrast to this proposition, when exogenous TMPRSS2 was present on Vero E6- and
A549-ACE2 cells, we show that apilimod was unable to protect cells from SARS-CoV-2 infec-
tion. We speculate that this is because the protease activity of TMPRSS2 might promote infec-
tion via direct fusion with the plasma membrane. This suggests that PIKfyve inhibition will
only prove clinically effective if combined with effective protease inhibition. In addition, we
demonstrated that modified Vero E6 and A549 cell systems were more permissive to
SARS-CoV-2 infection and are ideal cell culture systems for isolating clinical viruses and inves-
tigating viral plaque phenotypes, which can vary considerably. Thus, these relatively simple
tools are useful for dissecting the biology of SARS-CoV-2.
A key advantage of our COVID-19 coronavirus resource toolkit is that all antibodies (and
corresponding proteins and cDNAs) listed, our lentiviral constructs (and stable Vero E6 and
A549 cell lines), and our DNA-launched SARS-CoV-2 RG constructs are openly available
through our not-for-profit web interface (antibodies, protein, rescue plasmids at https://
mrcppu-covid.bio/; cell lines and virus strains have been deposited at the UK National Insti-
tute for Biological Standards and Controls; www.nibsc.org). By making this toolkit available to
the global research community, these resources will fast-track investigation of many aspects of
COVID-19 research, including drug discovery and vaccine development.
Materials and methods
DNA-launched SARS-CoV-2 plasmid construction
pCC1-4K-SARS-CoV-2-Wuhan-Hu1 (MT926410) and its derivatives, pCC1-4K-SARS-CoV-
2-mCherry (MT926411), pCC1-4K-SARS-CoV-2-NLuc (MT926412), and pCC1-4K-SARS-
CoV-2-ZsGreen (MW289908) were assembled from synthetic DNA fragments (Genscript).
The clones were assembled from 5 synthetic DNAs assembled in a stepwise fashion using con-
ventional restriction enzyme cloning.
Rescue of infectious virus
A total of 3 μg of plasmid DNA (containing icDNA of SARS-CoV-2) and 3 μl of Lipofectamine
LTX with 3 μl of PLUS reagent were used to transfect BHK-21 cells (ECACC) in 6-well plates.
On the next 3 days posttransfection, supernatant was transferred to Vero E6 cultures in T25
flasks. Virus was allowed to propagate in Vero E6 cells for a further 4 days before harvesting
the P0 stock. Infectious titres were enumerated by counting infected foci or via plaque assay.
Rescued virus was used to infect Vero E6 cells in 96-well plates. For the Nanoluc assay, cells
were lysed using a passive lysis buffer (Promega, cat#E1941) at 24 hpi. NanoLuc activity was
determined using the Nano-Glo Luciferase Assay kit (Promega, Cat# N1130) and measured
using a GloMax Luminometer (Promega).
Modified cell lines
The pLV-EF1a-IRES-Hygro (Addgene plasmid #85134) and pLV-EF1a-IRES-Neo (Addgene,
plasmid #85139) lentiviral vectors were modified to encode synthesised (Integrated DNA
Technologies) ACE2 (GenBank NM_001371415.1) and TMPRSS2 (GenBank NM_005656).
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Lentiviral vectors were produced through transient transfection as described previously [42]
and used to modify A549 cells (ATCC#CCL-185; generous gift from Prof. Ben Hale, validated
by STR analysis (Eurofins)) and Vero E6 cells (ATCC#CRL-1586; generous gift of Prof.
Michele Bouloy) that were cultured and transduced under standard culture conditions.
Isolation of SARS-CoV-2 viruses from clinical samples
Sputum and BAL residual clinical samples from SARS-CoV-2-infected individuals were
obtained for culture and used to inoculate Vero E6 or VAT cells in T25 flasks. Samples were
harvested between 48 and 96 h postinfection, depending on the severity of CPE. Viral titers
were determined by plaque assay.
Sequencing and metagenomics of isolated SARS-CoV-2 viruses
To determine the sequence of CVR-GLA-1, CVR-GLA-2, and CVR-GLA-3 isolated from clin-
ical samples (CVR837, CVR2224, CVR3899_BAL) and the RG-rescued SARS-CoV-2 viruses,
RNA was extracted from culture supernatant using a hybrid Trizol-RNeasy protocol. Library
was made from cDNA using Kapa LTP Library Preparation Kit for Illumina Platforms (Kapa
Biosystems, cat# KK8232). The sequencing of the libraries was carried out on Illumina’s Next-
Seq 550 System (Illumina, cat# SY-415-1002).
Plaque assays
Monolayers of A549 or Vero E6 cells and their ACE2/TMPRSS2 derivatives were prepared by
seeding 2.5 × 105 cells/well in 12-well plates, and plaque assays were executed using standard
conditions. Briefly, a 1-ml overlay of MEM/0.6% Avicel RC-591/2% FCS was used, and fixed
plates were stained with Coomassie Blue staining solution (0.1% Coomassie Brilliant Blue R-
250/45% methanol/10% acetic acid) before scanning using a photo scanner (Epson Expression
1680 Pro).
Well-clearance/monolayer integrity CPE assay
Cells were seeded in optical 96-well plates (Perkin Elmer CellCarrier-96 Ultra Microplates
Cat# 6055302) The following day, the cells were incubated with 10 μM to 20 nM of the various
compounds. The cells were then mock infected or infected with a predetermined dose of
SARS-CoV-2 that would cause substantial CPE by 72 h postinfection. Fixed plates were stained
(0.1% Coomassie Brilliant Blue R-250/45% methanol/10% acetic acid) and scanned using a
Celigo imaging cytometer (Nexcelom), allowing monolayer integrity to be quantified (to facili-
tate quantification of well-clearance to assess virus growth and toxicity). Dead cell protease
activity was measured in the same plates using the CytoTox-Glo Cytotoxicity Assay (Promega)
in accordance with the manufacturer’s instructions.
Generation of coronavirus antibodies
N-terminal GST fusion proteins for each coronavirus protein were used as antigens, and sheep
were immunised with each antigen, followed by up to 5 further injections 28 days apart, with
bleeds performed 7 days after each inoculation. Antibodies were subsequently affinity purified
from serum using N-terminal MBP-tagged recombinant protein. All antibodies (and associ-
ated proteins and cDNA clones) generated in this paper are openly available at: https://
mrcppu-covid.bio/.
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Ethics statement
This project falls under the scope and authority of project licence P134D890E, issued by the
UK Home Office in accordance with the Animals (Scientific Procedures) Act 1986. This
licence will stay in force, unless revoked earlier, until 2 April 2024. Prior to submission to the
Home Office, the application for the licence was scrutinised by the University of Dundee Ethi-
cal Review Committee, which approved the proposal at its meeting in March 2019. The Com-
mittee (now termed the Welfare and Ethical Use of Animals Committee) is a subcommittee of
the University Court, its highest governing body. All projects undertaken under the licence are
reviewed in terms of scientific rigor and possible alternative methods to avoid animal use, as
well as AWERB in terms of welfare.
Immunofluorescence
Cells infected with SARS-CoV-2 were fixed and permeabilised in 8% formaldehyde/1%
Triton X-100 at designated time points postinfection. DAPI (Thermo Fisher Scientific, cat#
P36395) was included in the mounting medium, and slides were stained with primary sheep
anti-coronavirus antibodies (1:500) and a rabbit anti-sheep secondary antibody (Abcam cat#
ab150182) at a 1:1000 dilution before imaging (Zeiss LSM 880 confocal microscope). Alterna-
tively, fixed and permeabilised cells were labelled using a mouse anti-N (nucleocapsid) IgG
antibody (SinoBiologicals; cat# 40143-MM08), which was detected using an AlexaFluor
488-conjugated goat anti-mouse secondary antibody (Life Technologies; cat# A28175). Cells
were subsequently counterstained with DAPI (1 μg/ml) and mounted using ProLong Gold
antifade (Life Technologies; cat# P36930). Sequential channels were acquired as z-stacks
(1.2 μm step) using an Olympus FV3000 confocal microscope and processed using Imaris soft-
ware (v 9.0.2; Bitplane).
For the enumeration of infected foci, the sheep anti-SARS-CoV-2 N antibody was used (at
a 1:500 dilution) and visualised using donkey anti-sheep antibody (A11015, Thermo Fisher
Scientific, 1:1000 dilution) prior to scanning (Celigo, Nexcelom).
Immunoprecipitation
At 3 days postinfection (at MOI 0.1), cells were trypsinised and rinsed in ice cold PBS before
being lysed in ice-cold lysis buffer [43]. IPs were set up overnight at 4˚C with the antibody
and protein lysate in a ratio of 3 μg of antibody per mg of protein lysate. The immunoprecip-
itated proteins were subjected to SDS-PAGE and then transferred to PVDF membranes
(Merck Millipore, IPFL00010), which were then incubated with their respective biotinylated
primary antibodies (0.5 to 1.0 mg/ml). Bands were visualised (LI-COR Odyssey CLx imaging
system) using labelled streptavidin (DyLight 680/800, Thermo Fisher Scientific, 21848/
21851).
Western blotting
Briefly, sonicated cell lysates were resolved using Novex 4% to 12% acrylamide gels (Life Tech-
nologies) before wet-transfer onto nitrocellulose membranes (Sigma Aldrich, cat#
GE10600003), after which membranes were probed with the indicated primary antibody (full
list of antibodies and their availability found in S2 Table) in SEA BLOCK (Thermo Scientific,
cat# 37527), unless otherwise specified. Bands were visualised using DyLight-labelled second-
ary antibodies (Thermo Fisher Scientific) prior to scanning with a Li-Cor Odyssey CLx imag-
ing system.
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Materials availability
All sheep CoV antibodies (and corresponding proteins and cDNAs) listed, lentiviral constructs
(and stable Vero E6 and A549 cell lines), and DNA-launched SARS-CoV-2 RG constructs are
openly available through a not-for-profit web interface (antibodies, proteins, rescue plasmids
at https://mrcppu-covid.bio/; cell lines and virus strains have been deposited at the UK
National Institute for Biological Standards and Controls; www.nibsc.org).
Supporting information
S1 Fig. Sequencing coverage of the sequenced rescue plasmids and rescued viruses. (A)
Summary plots of the number of reads mapping to the passaged plasmids from Fig 1B. (B)
Summary plots of the number of reads mapping to the SARS-CoV-2-mCherry, NLuc, and
ZsGreen rescue plasmids from the sequenced plasmid and the sequenced rescued virus (for
each rescue system). NLuc, Nanoluciferase; SARS-CoV-2, Severe Acute Respiratory Syndrome
Coronavirus 2; wt, wild type.
(PDF)
S2 Fig. Validation of the antibodies generated in this study by indirect immunofluores-
cence. (A, B) As in Fig 2C, Vero E6 cells were uninfected (mock) or infected with SARS-CoV-
2 England-02 at an MOI of 0.1 for 48 h before fixation/permeabilisation. Cells were stained
with primary sheep antibodies diluted at 1:500 and secondary rabbit anti-sheep Alexa 555
diluted at 1:1,000. MOI, multiplicity of infection; SARS-CoV-2, Severe Acute Respiratory Syn-
drome Coronavirus 2.
(PDF)
S3 Fig. Validation of the antibody reactivity by western blotting. (A, B) As in Fig 2D, Vero
E6 cells were uninfected (mock) or infected with SARS-CoV-2 England-02 at an MOI of 0.1 or
1 (as indicated) for 72 h prior to WB of whole cell lysates. Arrows indicate the band of interest.
MOI, multiplicity of infection; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus
2; WB, western blotting.
(PDF)
S4 Fig. Cross-reactivity of coronavirus nucleocapsid (N) and envelope (E) proteins. (A)
WB analysis of cross-reactivity of N-specific antibodies to SARS-CoV, MERS-CoV, HCoV
229E, and HCoV OC43 to the N protein of SARS-CoV-2. Vero E6 cells were mock infected
(mock) or infected with SARS-CoV-2 England-02 at an MOI of 0.1 or 1 for 72 h and probed as
in S3 Fig. (B) A comparison of IP results for the N proteins from SARS-CoV, MERS-CoV,
HCoV 229E, and HCoV OC43. As in Fig 2E, Vero E6 cells were uninfected (mock) or infected
with SARS-CoV-2 England-02 at an MOI of 0.1 for 3 days, followed by lysis, IP, and blotting
with the indicated N protein. (C) As in (B) but for the E proteins of SARS-CoV and MERS-
CoV. (D) WB analysis as in (A) but using MERS-CoV and SARS-CoV E antibodies. HCoV,
human coronavirus; IB, immunoblotting; IP, immunoprecipitation; MERS-CoV, Middle East
Respiratory Syndrome Coronavirus; MOI, multiplicity of infection; SARS-CoV-2, Severe
Acute Respiratory Syndrome Coronavirus 2; WB, western blotting.
(PDF)
S5 Fig. Validation of antibody reactivity by immunoprecipitation. (A, B) As in Fig 2E, Vero
E6 cells were uninfected (mock) or infected with SARS-CoV-2 England-02 at an MOI of 0.1
for 3 days. The cells were then lysed, and the viral proteins immunoprecipitated and detected
by WB using the indicated antibodies. No specific bands were present in the infected cells for
the SARS-CoV-2 E antibody. IB, immunobloting; IP, immunoprecipitation; MOI, multiplicity
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of infection; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; WB, western
blotting.
(PDF)
S6 Fig. A demonstration of the utility of the modified AA and AAT cell lines for conduct-
ing phenotypic assays. (A) Anti-SARS-CoV-2 dose response curves of a panel of compounds
using the well-clearance assay in AA cells and AAT cells (Fig 4K–4N) multiplexed with a dead
cell protease toxicity assay. The mean and standard error from 4 replicate experiments is plot-
ted. The apilimod panels (top right) plot the corresponding toxicity data to the data included
in Fig 4L. The labels for CsA and HCQ are abbreviated. (B) As in panel A, an extended dose
response of camostat in AAT cells is shown. The data underlying S6A and S6B Fig may be
found in S1 Data. AA, A549-ACE2; AAT, A549-ACE2-TMPRSS2; CsA, cyclosporine A; HCQ,
hydroxychloroquine; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.
(PDF)
S1 Text. Extended Materials and methods.
(PDF)
S1 Table. Sequence variation in passaged SARS-CoV-2-mCherry and SARS-CoV-2
CVR-GLA-1.
(XLSX)
S2 Table. Reagents and resources.
(PDF)
S1 Data. Underlying data.
(XLSX)
S1 Raw Images. Raw data image files.
(PDF)
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